RiverVest Venture Partners related stories
All articles and analysis
RiverVest Venture Partners Promotes John McKearn to Managing DirectorRiverVest Venture Partners promoted John McKearn to managing director. McKearn joined RiverVest as a venture partner in 2008. RiverVest is a St. Louis, Mo.-based venture capital firm that invests in emerging medical technology and biopharmaceutical companies
- IDEV Technologies raises $46M Series D funding
Medical technologies company IDEV Technologies has completed a $46 million Series D round of financing. New investors were Piper Jaffray & Co.'s Merchant Banking Fund and what the company described as “a leading strategic global healthcare company” were the two new investors, while return investors included PTV Sciences, Bay City Capital, RiverVest Venture Partners and Heron Capital.
- Week in deals, Sept. 20, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- peHUB Wire: Wednesday, September, 15, 2010
Editor's Note: Today's guest column comes from Rob Morris, managing partner of buyout shop Olympus Partners.
- peHUB Wire: Wednesday, September, 15, 2010
Editor's Note: Today's guest column comes from Rob Morris, managing partner of buyout shop Olympus Partners.
- Tryton Medical Closes $20 Million Series D Funding Round
Tryton Medical Inc., a Durham, N.C.-based developer of stents designed to treat bifurcation lesions, closed a $20 million Series D round of financing. Current investors PTV Sciences, RiverVest Venture Partners and Spray Venture Partners participated in the round. The financing was lead by Arnerich Massena. Arnerich Massena’s Russell J. Rottiers joined Tryton as a director.
- Week in deals, Sept. 13, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- Otonomy Inc. Closes Series B Financing Round At $38.5 Million
San Diego, Calif.-based Otonomy Inc. raised $38.5 million via a Series B financing. The round was co-led by Novo Ventures and RiverVest Venture Partners, and joined by Domain Associates and TPG Biotech. The clinical-stage biopharmaceutical concern previously raised around $10 million in Series A funding with Avalon Ventures in June 2010. Avalon participated in the latest round.
- Gilead Buying CGI Pharma for $120 Million
Gilead Sciences Inc. (Nasdaq: GILD) has agreed to acquire CGI Pharmaceuticals Inc., a Branford, Conn.-based drug developer focused on small molecule chemistry and kinase biology. The deal is valued at $120 million, the majority of which is an up-front cash payment.
- RiverVest Venture Partners Promotes Niall O'Donnell
RiverVest Venture Partners has promoted Niall O'Donnell to principal. O'Donnell joined the life sciences-focused firm as a Kauffman Fellow in May 2006, and continued on as an associate.